Indications
Therapeutic Asset Ratings
9,920 results matching 1 filter
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Rimiducid
Her2-Receptor Negative Breast Cancer
Memorial Sloan Kettering Cancer Center
P1
CC
(43)
Rimiducid
Nasopharyngeal Carcinoma
Poseida Therapeutics, Inc.
P1
CC
(43)
Rimiducid
Neoplasm
M.D. Anderson Cancer Center
P1
CC
(43)
Rimiducid
Follicular Lymphoma
Poseida Therapeutics, Inc.
P1
CC
(43)
Rimiducid
X-Linked Lymphoproliferative Syndrome
Baylor College of Medicine
P1
CC
(43)
Rituximab
Glioblastoma
University of Pennsylvania
P1
CC
(43)
Rituximab
Diffuse Large B-Cell Lymphoma Of The Central Nervous System
National Cancer Institute (NCI)
P1
CC
(43)
Rivoceranib
Prostate Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.
P1
CC
(43)
rk-582
Metastatic Malignant Neoplasm In The Colon
Eiji Shinozaki
P1
CC
(43)
Rndo-564
Gastroesophageal Junction Adenocarcinoma
Rondo Therapeutics
P1
CC
(43)
RO7567132
Neoplasm
Hoffmann-La Roche
P1
CC
(43)
ro7790121
Metabolic Dysfunction-Associated Steatohepatitis
Hoffmann-La Roche
P1
CC
(43)
Rocakinogene Sifuplasmid
Hepatitis
National Cancer Institute (NCI)
P1
CC
(43)
Rocakinogene Sifuplasmid
Hepatitis C Virus Infection
National Cancer Institute (NCI)
P1
CC
(43)
Rocbrutinib
B-Cell Non-Hodgkin Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.
P1
CC
(43)
Roflumilast
Diffuse Large B-Cell Lymphoma
The University of Texas Health Science Center at San Antonio
P1
CC
(43)
Roginolisib
Myelofibrosis
iOnctura
P1
CC
(43)
Roginolisib
Non-Hodgkin Lymphoma
iOnctura
P1
CC
(43)
Romidepsin
Adult T-Cell Leukemia/Lymphoma
National Cancer Institute (NCI)
P1
CC
(43)
Romidepsin
Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
National Cancer Institute (NCI)
P1
CC
(43)
Romiplostim
Acute Myeloid Leukemia
First Affiliated Hospital of Zhejiang University
P1
CC
(43)
Romiplostim
Myelodysplastic Syndrome
First Affiliated Hospital of Zhejiang University
P1
CC
(43)
Ropeginterferon Alfa-2B
Cancer
PharmaEssentia
P1
CC
(43)
Ropeginterferon Alfa-2B
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
H. Lee Moffitt Cancer Center and Research Institute
P1
CC
(43)
Rosuvastatin
Castration-Resistant Prostate Carcinoma
Aragon Pharmaceuticals, Inc.
P1
CC
(43)
Showing 4076 to 4100 of 9,920 assets
Previous
Page 164 of 397
Next